Telaprevir-induced renal impairment: three clinical cases and a review of the literature.

@article{Andreocchi2015TelaprevirinducedRI,
  title={Telaprevir-induced renal impairment: three clinical cases and a review of the literature.},
  author={Laura Andreocchi and Valeriu Toma and Aliza Canonica-Lepori and Lorenzo Magenta and S{\'a}ndor Gy{\"o}rik and Lisa Pellegrini and Enos Bernasconi},
  journal={Infectious diseases},
  year={2015},
  volume={47 9},
  pages={662-7}
}
Telaprevir (TPV) is one of the NS3/4A serine protease inhibitors on the market for the treatment of chronic hepatitis C genotype 1 in combination with peginterferon alpha and ribavirin. Well-documented potential adverse reactions of TPV are hematological, skin, and gastro-intestinal disorders. Until now, there were no conclusive data from clinical trials… CONTINUE READING